相关实验视频

Updated: Jun 21, 2025

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

与lacosamide相关的心脏不良事件:FAERS数据库的不成比例分析

Chengcheng Yang¹, Wanqi Zhao², Huihui Chen³

¹Department of Pharmacy, The First People's Hospital of Shangqiu, Shangqiu, 476000, China. ycc424@163.com.

Scientific reports

|July 13, 2024

概括

第三代抗药物拉科萨米德在真实世界的数据中显示了心脏不良事件 (AE). 对812次心脏性意外事件的分析发现了17个显著信号,大多数病例出现在早期,随着时间的推移风险下降.

科学领域:

药物监督药物监督药物监督
心脏病学心脏病学
神经学神经学

背景情况:

拉科萨米德是一种第三代抗药物 (AED).
关于lacosamide心脏不良事件 (AEs) 的现实世界数据有限.
需要进行全面的心脏安全评估.

研究的目的:

为了评估lacosamide的心脏安全概况.
使用现实世界的数据来识别和量化与lacosamide相关的心脏副作用.
提高医疗保健专业人员对潜在心脏风险的认识.

主要方法:

使用了美国食品和药物管理局不良事件报告系统 (FAERS) 数据库 (2013 Q12022 Q4).
使用不成比例分析计算报告几率比率 (ROR) 来检测安全信号.
应用了严重与非严重病例的统计分析和信号优先级的评级尺度.

主要成果:

鉴定了812个与lacosamide相关的心脏副作用.
检测到92个潜在的安全信号,其中17个达到统计学意义 (ROR 95% CI下限>1).
观察到心脏AE的早期发病模式,中位数发病时间为中度的10天,弱优先信号的54天,表明随着时间的推移风险下降.

结论:

拉科萨米德表现出心脏安全概况,其特点是早期出现的不良事件.
与lacosamide相关的心脏AE风险似乎随着时间的推移而降低.
这些发现强调了监测心脏AE在接受lacosamide治疗的患者中的重要性.

关键词:

心脏不良事件的心脏不良事件不成比例性分析的分析.在FAERS数据库中,我们可以找到FAERS数据库.拉科萨米德是一种乳胺.报告几率比率是报告几率比率.

更多相关视频

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

相关概念视频

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...